Stock Markets June 4, 2026 04:46 PM

Moody's Raises Tenet Healthcare Rating as Debt Levels Fall

Upgrade reflects sustained deleveraging, ambulatory care growth and strong liquidity; outlook set to stable

By Priya Menon THC

Moody's upgraded Tenet Healthcare's corporate family rating and certain debt classes, citing significant deleveraging over the past 24 months driven by EBITDA growth and debt reduction. The ratings action comes with a stable outlook and reflects expectations for continued revenue and EBITDA expansion through ambulatory care, disciplined capital allocation, and maintained leverage in a specified range.

Moody's Raises Tenet Healthcare Rating as Debt Levels Fall
THC

Key Points

  • Moody's raised Tenet's Corporate Family Rating to Ba2 from Ba3 and set the outlook to stable from positive; senior secured first lien notes upgraded to Ba2 and senior unsecured notes to B1.
  • Upgrade driven by sustained deleveraging over the past 24 months, supported by strong EBITDA growth and significant debt paydown; future revenue and EBITDA growth expected to come primarily from ambulatory care expansion.
  • Tenet reported over $2.9 billion in cash and an almost fully available $1.9 billion ABL revolver as of March 31, 2026; Moody's expects more than $1.5 billion in annual free cash flow after distributions to non-controlling interests.

Moody's Ratings has raised Tenet Healthcare Corporation's (NYSE:THC) Corporate Family Rating to Ba2 from Ba3 and revised the outlook to stable from positive, the ratings agency said. Alongside the CFR upgrade, Moody's also upgraded Tenet's senior secured first lien notes to Ba2 from Ba3 and its senior unsecured notes to B1 from B2.

The agency framed the upgrade as a response to Tenet's sustained deleveraging over the past 24 months, attributing the improvement to robust EBITDA growth and meaningful debt paydown during that period. Moody's said it expects the company to continue expanding revenue and EBITDA, largely through growth in its ambulatory care operations.

Moody's noted that the upgrade also incorporates an expectation that Tenet will adhere to disciplined financial policies. Specifically, the agency expects share repurchases and other distributions to be managed in line with free cash flow generation, and for the company to maintain a debt-to-EBITDA ratio in the 3.5 times to 4.5 times range.

In assessing the company's credit profile, Moody's described Tenet's Ba2 CFR as reflecting its sizable scale, good business diversity, moderately high financial leverage and very good liquidity. The agency referenced a contractual development in January 2026: Tenet and CommonSpirit Health (rated A3 with a stable outlook) agreed to end early a relationship under which a Tenet subsidiary provided revenue cycle management services to CommonSpirit.

Moody's acknowledged that Tenet plans to offset the lost revenue from that contract by growing its revenue cycle management services with other clients.

On liquidity, Tenet reported having over $2.9 billion in cash and an approximately $1.9 billion asset-based lending revolver that was almost entirely available as of March 31, 2026. Moody's also projected that Tenet will produce more than $1.5 billion in annual free cash flow after distributions to non-controlling interests.


The ratings agency outlined scenarios that could prompt further rating movement. An upgrade could follow if Tenet captures additional benefits from cost and operating initiatives, including higher profit margins, and sustains debt-to-EBITDA below 3.5 times. Conversely, a downgrade could arise if the company encounters setbacks in executing strategic initiatives or if debt-to-EBITDA remains above 4.5 times for a sustained period.

Risks

  • Ratings could be downgraded if Tenet experiences missteps in its strategic initiatives, which would affect the healthcare services and hospital sectors.
  • Sustained debt-to-EBITDA above 4.5 times would also risk a downgrade, presenting financial and credit risks for the company and bond investors.

More from Stock Markets

S&P Global Upholds Fast-Entry Rules Ahead of SpaceX Public Debut Jun 4, 2026 Insperity Shares Climb After CEO Buys 233,000 Shares Jun 4, 2026 SpaceX Signals Firmness on $135 IPO Price as Roadshow Begins Jun 4, 2026 CME Chief Warns CFTC Approval of Perpetual Crypto Futures Could Create Systemic Risk Jun 4, 2026 AmperCap Raises $125 Million in NASDAQ Listing as It Targets U.S.-Mexico Middle-Market Deals Jun 4, 2026